Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved ...

Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, ...

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Myriad Genetics pioneered and was the market leader in BRCA testing for over ten years. Analysts write that CEO Paul Diaz has successfully addressed Myriad's operational and innovation challenges ...

Myriad Genetics, Inc. has announced a collaboration with sports broadcaster Hannah Storm, who recently shared her experience with breast cancer.

Debt Management: Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, ...

A leading medical society is calling on Myriad Genetics Inc.MYGN 1.20 % increase; green up pointing triangle and other lab companies to share proprietary data from their genetic testing in a ...

Genetic testing firm Myriad Genetics has tapped scientist and veteran biopharma lawyer Jennifer Fox to be its legal chief starting in September, the company announced Wednesday. Fox comes from ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...